Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.


Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
02 2021
Historique:
received: 29 06 2020
revised: 24 11 2020
accepted: 25 11 2020
pubmed: 29 12 2020
medline: 4 2 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

We aimed to ascertain the cumulative risk of fatal or critical care unit-treated COVID-19 in people with diabetes and compare it with that of people without diabetes, and to investigate risk factors for and build a cross-validated predictive model of fatal or critical care unit-treated COVID-19 among people with diabetes. In this cohort study, we captured the data encompassing the first wave of the pandemic in Scotland, from March 1, 2020, when the first case was identified, to July 31, 2020, when infection rates had dropped sufficiently that shielding measures were officially terminated. The participants were the total population of Scotland, including all people with diabetes who were alive 3 weeks before the start of the pandemic in Scotland (estimated Feb 7, 2020). We ascertained how many people developed fatal or critical care unit-treated COVID-19 in this period from the Electronic Communication of Surveillance in Scotland database (on virology), the RAPID database of daily hospitalisations, the Scottish Morbidity Records-01 of hospital discharges, the National Records of Scotland death registrations data, and the Scottish Intensive Care Society and Audit Group database (on critical care). Among people with fatal or critical care unit-treated COVID-19, diabetes status was ascertained by linkage to the national diabetes register, Scottish Care Information Diabetes. We compared the cumulative incidence of fatal or critical care unit-treated COVID-19 in people with and without diabetes using logistic regression. For people with diabetes, we obtained data on potential risk factors for fatal or critical care unit-treated COVID-19 from the national diabetes register and other linked health administrative databases. We tested the association of these factors with fatal or critical care unit-treated COVID-19 in people with diabetes, and constructed a prediction model using stepwise regression and 20-fold cross-validation. Of the total Scottish population on March 1, 2020 (n=5 463 300), the population with diabetes was 319 349 (5·8%), 1082 (0·3%) of whom developed fatal or critical care unit-treated COVID-19 by July 31, 2020, of whom 972 (89·8%) were aged 60 years or older. In the population without diabetes, 4081 (0·1%) of 5 143 951 people developed fatal or critical care unit-treated COVID-19. As of July 31, the overall odds ratio (OR) for diabetes, adjusted for age and sex, was 1·395 (95% CI 1·304-1·494; p<0·0001, compared with the risk in those without diabetes. The OR was 2·396 (1·815-3·163; p<0·0001) in type 1 diabetes and 1·369 (1·276-1·468; p<0·0001) in type 2 diabetes. Among people with diabetes, adjusted for age, sex, and diabetes duration and type, those who developed fatal or critical care unit-treated COVID-19 were more likely to be male, live in residential care or a more deprived area, have a COVID-19 risk condition, retinopathy, reduced renal function, or worse glycaemic control, have had a diabetic ketoacidosis or hypoglycaemia hospitalisation in the past 5 years, be on more anti-diabetic and other medication (all p<0·0001), and have been a smoker (p=0·0011). The cross-validated predictive model of fatal or critical care unit-treated COVID-19 in people with diabetes had a C-statistic of 0·85 (0·83-0·86). Overall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history. None.

Sections du résumé

BACKGROUND
We aimed to ascertain the cumulative risk of fatal or critical care unit-treated COVID-19 in people with diabetes and compare it with that of people without diabetes, and to investigate risk factors for and build a cross-validated predictive model of fatal or critical care unit-treated COVID-19 among people with diabetes.
METHODS
In this cohort study, we captured the data encompassing the first wave of the pandemic in Scotland, from March 1, 2020, when the first case was identified, to July 31, 2020, when infection rates had dropped sufficiently that shielding measures were officially terminated. The participants were the total population of Scotland, including all people with diabetes who were alive 3 weeks before the start of the pandemic in Scotland (estimated Feb 7, 2020). We ascertained how many people developed fatal or critical care unit-treated COVID-19 in this period from the Electronic Communication of Surveillance in Scotland database (on virology), the RAPID database of daily hospitalisations, the Scottish Morbidity Records-01 of hospital discharges, the National Records of Scotland death registrations data, and the Scottish Intensive Care Society and Audit Group database (on critical care). Among people with fatal or critical care unit-treated COVID-19, diabetes status was ascertained by linkage to the national diabetes register, Scottish Care Information Diabetes. We compared the cumulative incidence of fatal or critical care unit-treated COVID-19 in people with and without diabetes using logistic regression. For people with diabetes, we obtained data on potential risk factors for fatal or critical care unit-treated COVID-19 from the national diabetes register and other linked health administrative databases. We tested the association of these factors with fatal or critical care unit-treated COVID-19 in people with diabetes, and constructed a prediction model using stepwise regression and 20-fold cross-validation.
FINDINGS
Of the total Scottish population on March 1, 2020 (n=5 463 300), the population with diabetes was 319 349 (5·8%), 1082 (0·3%) of whom developed fatal or critical care unit-treated COVID-19 by July 31, 2020, of whom 972 (89·8%) were aged 60 years or older. In the population without diabetes, 4081 (0·1%) of 5 143 951 people developed fatal or critical care unit-treated COVID-19. As of July 31, the overall odds ratio (OR) for diabetes, adjusted for age and sex, was 1·395 (95% CI 1·304-1·494; p<0·0001, compared with the risk in those without diabetes. The OR was 2·396 (1·815-3·163; p<0·0001) in type 1 diabetes and 1·369 (1·276-1·468; p<0·0001) in type 2 diabetes. Among people with diabetes, adjusted for age, sex, and diabetes duration and type, those who developed fatal or critical care unit-treated COVID-19 were more likely to be male, live in residential care or a more deprived area, have a COVID-19 risk condition, retinopathy, reduced renal function, or worse glycaemic control, have had a diabetic ketoacidosis or hypoglycaemia hospitalisation in the past 5 years, be on more anti-diabetic and other medication (all p<0·0001), and have been a smoker (p=0·0011). The cross-validated predictive model of fatal or critical care unit-treated COVID-19 in people with diabetes had a C-statistic of 0·85 (0·83-0·86).
INTERPRETATION
Overall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history.
FUNDING
None.

Identifiants

pubmed: 33357491
pii: S2213-8587(20)30405-8
doi: 10.1016/S2213-8587(20)30405-8
pmc: PMC7832778
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-93

Subventions

Organisme : Wellcome Trust
ID : 201492/Z/16/Z
Pays : United Kingdom

Investigateurs

Alice Whettlock (A)
Allan McLeod (A)
Andrew Gasiorowski (A)
Andrew Merrick (A)
Andy McAuley (A)
April Went (A)
Calum Purdie (C)
Colin Fischbacher (C)
Colin Ramsey (C)
David Bailey (D)
David Henderson (D)
Eisin McDonald (E)
Genna Drennan (G)
Graeme Gowans (G)
Graeme Reid (G)
Heather Murdoch (H)
Jade Carruthers (J)
Josie Murray (J)
Karen Heatlie (K)
Lorraine Donaldson (L)
Martin Paton (M)
Martin Reid (M)
Melissa Llano (M)
Michelle Murphy-Hall (M)
Ross Hall (R)
Ross Cameron (R)
Susan Brownlie (S)
Adam Gaffney (A)
Aynsley Milne (A)
Christopher Sullivan (C)
Edward McArdle (E)
Elaine Glass (E)
Johanna Young (J)
William Malcolm (W)
Jodie McCoubrey (J)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

JAMA. 2015 Jan 6;313(1):37-44
pubmed: 25562264
Stat Methods Med Res. 2019 Jun;28(6):1841-1851
pubmed: 29978758
Metabolism. 2020 Aug 22;112:154344
pubmed: 32835758
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
BMJ. 2020 Oct 20;371:m3731
pubmed: 33082154
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mayo Clin Proc. 2020 Oct;95(10):2189-2203
pubmed: 33012349
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Lancet. 2020 Mar 21;395(10228):931-934
pubmed: 32164834
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Circulation. 2018 Dec 11;138(24):2774-2786
pubmed: 29950404
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
PLoS One. 2020 Aug 27;15(8):e0238281
pubmed: 32853230
PLoS Med. 2020 Oct 20;17(10):e1003374
pubmed: 33079969
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Int J Epidemiol. 1999 Oct;28(5):964-74
pubmed: 10597998
Diabetologia. 2020 Aug;63(8):1500-1515
pubmed: 32472191
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32474598
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471

Auteurs

Stuart J McGurnaghan (SJ)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Amanda Weir (A)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Jen Bishop (J)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Sharon Kennedy (S)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Luke A K Blackbourn (LAK)

Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

David A McAllister (DA)

Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Sharon Hutchinson (S)

School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.

Thomas M Caparrotta (TM)

Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Joseph Mellor (J)

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Anita Jeyam (A)

Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Joseph E O'Reilly (JE)

Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Sarah H Wild (SH)

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Sara Hatam (S)

Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Andreas Höhn (A)

Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Marco Colombo (M)

Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Chris Robertson (C)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.

Nazir Lone (N)

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Janet Murray (J)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Elaine Butterly (E)

Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

John Petrie (J)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Brian Kennon (B)

Queen Elizabeth University Hospital, Glasgow, UK.

Rory McCrimmon (R)

University of Dundee, Dundee, UK.

Robert Lindsay (R)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Ewan Pearson (E)

University of Dundee, Dundee, UK.

Naveed Sattar (N)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

John McKnight (J)

Western General Hospital, National Health Service Lothian Edinburgh, UK.

Sam Philip (S)

Grampian Diabetes Research Unit, Diabetes Centre, Aberdeen Royal Infirmary, Aberdeen, UK.

Andrew Collier (A)

School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.

Jim McMenamin (J)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Alison Smith-Palmer (A)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

David Goldberg (D)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Paul M McKeigue (PM)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Helen M Colhoun (HM)

Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Department of Public Health, National Health Service Fife, Kirkcaldy, UK. Electronic address: helen.colhoun@igmm.ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH